Clinical trials: Uveitis, Intermediate
Behçet's Disease
Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease
Relation between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease
- Trial name
- NCT06296004
- Testing
- Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Uveitis
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
The study aims to evaluate the potential role of ACTH gel in the management of non-infectious uveitis.
- Trial name
- ACTHAR (NCT02931175)
- Testing
- ACTH gel
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Quan Dong Nguyen
Non-infectious Intermediate, Posterior and Panuveitis
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.
- Trial name
- NCT03339102
- Where
- 17 sites in South Korea
- Volunteers
- 158 people
- Sponsor
- AbbVie
Behcet's Disease, Uveitis
Immunogenetic Mechanisms in Behcet's Disease
Background: Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases of legal blindness every year.
- Trial name
- NCT01109433
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Eye Institute (NEI)
Uveitis, Cystoid Macular Edema
The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema
Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema.
- Trial name
- NCT00893854
- Testing
- Diclophenac, Triamcinolone
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Uveitis
Leflunomide to Treat Uveitis
This study will investigate the safety and effectiveness of the drug Leflunomide to treat uveitis-an inflammation of the eye caused by an immune system abnormality.
- Trial name
- NCT00001863
- Testing
- Leflunomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
Uveitis
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- INSURE (NCT01095250)
- Testing
- AIN457
- Where
- 36 sites in United States, Canada and 11 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis, Intermediate Uveitis
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
The purpose of this study is to find out about the safety and effectiveness of two different doses the study drug, sirolimus, administered intravitreally in patients with uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- SAVE-2 (NCT01280669)
- Testing
- Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg
- Where
- United States
- Sponsor
- Stanford University
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis, Intermediate, Uveitis, Posterior
Study of the Effectiveness of Ozurdex for the Control of Uveitis
The main purpose of this study is to evaluate whether or not the dexamethasone pellet (Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g.
- Trial name
- NCT02049476
- Testing
- Dexamethasone pellet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Uveitis
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity.
- Trial name
- NCT05384249
- Testing
- Izokibep
- Where
- 69 sites in United States, Austria and 5 more
- Volunteers
- 96 people
- Sponsor
- ACELYRIN Inc.
Non-infectious Uveitis
Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis
Primary objective: safety and tolerability Secondary objectives: additional indicators of long term safety and indicators of clinical activity Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and…
- Trial name
- NCT03308045
- Testing
- pEYS606
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Eyevensys
Uveitis
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at…
- Trial name
- LINNAEA (NCT04706741)
- Testing
- Izokibep, Prednisone/Prednisolone
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- ACELYRIN Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- ENDURE (NCT01032915)
- Testing
- AIN457
- Where
- 94 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis, Anterior Uveitis
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision.
- Conditions
- Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis
- Trial name
- NCT02764697
- Testing
- H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Tampa Bay Uveitis Center, LLC
Uveitis
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- Trial name
- Visual II (NCT01124838)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 261 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Anterior Uveitis, Intermediate Uveitis
Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
This study investigates the variations in the retinal nerve fiber layer (RNFL) thickness during uncomplicated anterior and intermediate uveitis, respectively.
- Trial name
- NCT02879084
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- CHU de Quebec-Universite Laval